Ovarian Cancer

Latest News
November 13th 2024

Ovarian Cancer Survival Varies Widely Among Asian American Subgroups

October 29th 2024

HPV 16 and 18 Linked to Ovarian Cancer Risk

October 24th 2024

Prediagnosis Diet Improves Survival in Black Women With Deadly Ovarian Cancer

October 22nd 2024

Neoadjuvant Chemotherapy Becomes Leading Initial Treatment for Advanced Epithelial Ovarian Cancer

October 18th 2024

Increased Ovarian Cancer Risk Linked to Elevated Nitrogen Dioxide Exposure, Study Finds

Ovarian Cancer Guideline Updates 2024

Ronald D. Alvarez, MD, MBA, analyzes recent changes to NCCN guidelines for ovarian cancer care and provides updates on the latest clinical trial data.

Ronald D. Alvarez, MD, MBA, analyzes recent changes to NCCN guidelines for ovarian cancer care and provides updates on the latest clinical trial data.
Video Interviews
View All
November 7th 2024

Charting a Healthier Future: Improving Ovarian Cancer Survival for Black Women Through Dietary Adherence

November 5th 2024

Nourishing Survival: The Impact of Dietary Quality on Black Women With Ovarian Cancer

March 18th 2024

Closing Thoughts on the Current Ovarian Cancer Treatment Landscape

March 18th 2024

Harnessing Biomarkers & Molecular Profiling in Ovarian Cancer Treatment

February 12th 2021

Dr Whitney Goldsberry on the Future of PARP Inhibitors in Ovarian Cancer

February 6th 2021

Dr Whitney Goldsberry on Cost-Sharing Trends in PARP Inhibitors for Ovarian Cancer

December 30th 2020

Dr Bradley Monk Discusses Indications for PARP Inhibitors in Ovarian Cancer

December 28th 2020

Dr Bradley Monk on Response to PARP Inhibitors in Ovarian Cancer

December 26th 2020

Dr Bradley Monk on the Changing Regulatory Landscape of PARP Inhibitors

December 24th 2020

Dr Bradley Monk on Multidisciplinary Care With PARP Inhibitors

More News

3D ovarian cancer illustration | Image Credit: Dr_Microbe - stock.adobe.com
October 15th 2024

Mirvetuximab Soravtansine Effective in Patients With FRα+, Platinum-Sensitive Ovarian Cancer

Brooke McCormick
The phase 2 PICCOLO trial demonstrated that mirvetuximab soravtansine (Elahere; AbbVie) is effective and tolerable in heavily pre-treated patients with folate receptor alpha-positive (FRα+), platinum-sensitive ovarian cancer.
Mediterranean diet | Image Credit: fascinadora - stock.adobe.com
October 4th 2024

High Alternate Mediterranean Diet Scores Tied to Better Survival in Patients With Ovarian Cancer

Brooke McCormick
Higher pre- and postdiagnosis Alternate Mediterranean Diet (AMED) scores are associated with improved overall survival in patients with ovarian cancer.
National Ovarian Cancer Awareness Month | Image Credit: Rabin - stock.adobe.com
September 30th 2024

Ovarian Cancer Awareness Month: Prioritizing Early Detection, Bridging Equity Gaps

Brooke McCormick
September marked Ovarian Cancer Awareness Month, highlighting the importance of early detection and the need for equitable treatment access.
Ovarian cancer awareness ribbon | Image credit: SewcreamStudio - stock.adobe.com
September 27th 2024

5 Things to Know About Low-Grade Serous Ovarian Cancer

Pearl Steinzor
The first-ever Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day is dedicated to raising awareness, providing resources, and advocating for more research into this rare and recurrent form of ovarian cancer.
FDA office building | Image Credit: JHVEPhoto - stock.adobe.com
September 26th 2024

NXP800 Gains FDA Orphan Drug Status in ARID1a-Deficient Ovarian Cancers

Jordyn Sava
NXP800 was granted orphan drug designation from the FDA in ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.
EMA logo | Image Credit: Ricochet64 - stock.adobe.com
September 25th 2024

CHMP Recommends Mirvetuximab Soravtansine for FRα+ Ovarian Cancer

Ashling Wahner
The European Medicines Agency's (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended the marketing authorization of mirvetuximab soravtansine (Elahere; AbbVie) for folate receptor alpha–positive (FRα+), platinum-resistant epithelial ovarian cancer.
Ovarian cancer animation | Image Credit: Nuchjaree - stock.adobe.com
September 24th 2024

Olaparib/Cediranib Misses Survival End Points in Relapsed Ovarian Cancer Trial

Ashley Chan
Treatment with maintenance olaparib/cediranib demonstrated similar survival vs olaparib alone in platinum-sensitive relapsed ovarian cancer.
ovarian cancer animation | Image Credit: Lars Neumann - stock.adobe.com
September 21st 2024

Pan-Immune-Inflammation–Based Nomogram Predicts OS, PFS in Epithelial Ovarian Cancer

Brooke McCormick
Researchers developed a pan-immune-inflammation–based nomogram to accurately predict overall survival (OS) and progression-free survival (PFS) in patients with epithelial ovarian cancer
3D illustration of ovarian cancer cells | Image Credit: LASZLO - stock.adobe.com
September 11th 2024

Bevacizumab Significantly Improves Progression-Free Survival in Patients With Epithelial Ovarian Cancer

Brooke McCormick
Adding bevacizumab to the combination therapy of carboplatin and paclitaxel significantly improved progression-free survival (PFS) in patients with epithelial ovarian cancer (EOC) but not overall survival (OS).
Female patient and physician speaking | Image Credit: rocketclips - stock.adobe.com
August 31st 2024

Low Patient Involvement in First-Line Ovarian Cancer Treatment Decisions in Europe, US

Brooke McCormick
Researchers found low rates of patient involvement in first-line ovarian cancer treatment decisions in Europe and the US from 2017 to 2020 despite the increasing use of targeted therapies, like poly (ADP-ribose) polymerase inhibitors.
3D illustration of ovarian cancer | Image Credit: Dr_Microbe - stock.adobe.com
August 30th 2024

Symptom-Triggered Testing Detects Early-Stage Ovarian Cancer in 1 in 4 Women

Brooke McCormick
Symptom-triggered testing via the fast-track pathway identified early-stage high-grade serous ovarian cancer in 1 in 4 women, potentially leading to better survival outcomes.
clinician holding a CA-125 test | Image Credit: jarun011 - stock.adobe.com
August 29th 2024

CA-125 Test Accuracy for Ovarian Cancer Prediction Varies by Ethnicity

Brooke McCormick
The accuracy of the cancer antigen (CA)–125 test in predicting ovarian cancer varies by ethnicity, primarily due to factors like age and comorbidities rather than ethnicity itself.
3D illustration of hepatitis B | Image Credit: Destina - stock.adobe.com
August 15th 2024

Hepatitis B Virus Associated With Cervical Cancer, Not Ovarian or Endometrial Cancers

Brooke McCormick
Hepatitis B virus (HBV) is associated with an increased risk of cervical cancer but not ovarian or endometrial cancers.
2 male surgeons operating on patient | Image Credit: Gorodenkoff - stock.adobe.com
August 8th 2024

Dual-Surgeon Approach Lowers Anastomotic Leak Rates in Ovarian Cancer Surgery

Brooke McCormick
The involvement of 2 surgeons during cytoreductive debulking and bowel surgery in patients with epithelial ovarian cancer significantly reduces the rate of anastomotic leaks.
3D illustration of ovarian cancer | Image Credit: Lars Neumann - stock.adobe.com
August 6th 2024

Patients With Endometriosis May Have Higher Ovarian Cancer Risk

Brooke McCormick
Patients with endometriosis have a 4.2-fold greater ovarian cancer risk, highlighting the need for further research into the biological links between endometriosis subtypes and ovarian cancer.
dr diane mahoney
July 25th 2024

Dr Diane Mahoney on Tackling Ovarian Cancer Care Disparities

Brooke McCormick
In part 2 of our interview, Diane Mahoney, PhD, DNP, FNP-BC, WHNP-BC, APRN, advocates for a multidisciplinary, community-centered approach to reduce ovarian cancer care disparities and stresses the need for ongoing exploration of social, biological, and environmental factors affecting health outcomes.
dr diane mahoney
July 23rd 2024

Dr Diane Mahoney Uncovers Health Disparities Among Black, Hispanic Ovarian Cancer Survivors

Brooke McCormick
Diane Mahoney, PhD, DNP, FNP-BC, WHNP-BC, APRN, discusses her study on how social determinants of health impact the health perceptions of Black and Hispanic ovarian cancer survivors, highlighting significant health disparities.
what we're reading logo
July 18th 2024

What We’re Reading: Misleading ACA Ads; Codifying Roe v Wade; Ovarian Cancer Risk in Women With Endometriosis

AJMC Staff
Misleading ads are under scrutiny for their role in signing up consumers for Affordable Care Act (ACA) coverage without their permission; Sen Elizabeth Warren (D, Massachusetts) said there are enough votes in the Senate to suspend the filibuster to codify Roe v Wade in 2025 with a Democratic majority; women with endometriosis have about a fourfold risk of developing ovarian cancer.
Black female patient | Image Credit: Seventyfour - stock.adobe.com
July 17th 2024

SDOH Factors Impact Health Perceptions in Black, Hispanic Ovarian Cancer Survivors

Brooke McCormick
Social determinants of health (SDOH) factors significantly impact the overall health perceptions of Black and Hispanic ovarian cancer survivors.
Patient holding metformin prescription | Image Credit: Sherry Young - stock.adobe.com
July 9th 2024

Metformin Use Linked to Better Survival Rates in Patients With Ovarian Cancer

Brooke McCormick
Metformin use is linked to improved survival rates in patients with ovarian cancer, particularly among those with diabetes and serous cancers, though further research is needed to confirm these findings.
Drawing of a diverse group of people | Image Credit: Stafeeva - stock.adobe.com
July 2nd 2024

Minority Patients With Gynecologic Cancers More Likely to Receive Treatment at Academic Facilities

Brooke McCormick
Minority patients with gynecologic cancers are more likely than White patients to receive treatment at academic facilities, a recent study found.
3D illustration of ovarian cancer | Image Credit: Dr_Microbe - stock.adobe.com
June 30th 2024

Fertility-Sparing Surgery Outcomes Comparable With Radical Surgery in Stage I Epithelial Ovarian Cancer

Brooke McCormick
Researchers found no significant differences in disease-free survival, overall survival, and recurrence rates between fertility-sparing surgery and radical surgery for patients with stage I epithelial ovarian cancer.
Doctor holding animated uterus and ovaries anatomy | Image Credit: Orawan - stock.adobe.com
June 28th 2024

Study: NLR, PLR May Be Early Prognostic Markers for Patients With Ovarian Cancer

Brooke McCormick
High neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) are associated with worse progression-free survival and 5-year overall survival in patients with ovarian cancer.
Ovarian cancer | Image credit: Lars Neumann - stock.adobe.com
June 26th 2024

Fears, Concerns for Patients and Loved Ones Intensify Due to Recurrent Ovarian Cancer

Julia Bonavitacola
Supportive care interventions could help address concerns and help patients during the recurrence of ovarian cancer.
Medical team in operating room | Image Credit: Georgii - stock.adobe.com
June 25th 2024

Study Highlights Differences in Cytoreduction's Impact on Survival Among Ovarian Cancer Subtypes

Brooke McCormick
The association between residual tumor volume after primary cytoreduction and survival was less consistent in patients with low-grade serous ovarian carcinoma (LGSOC) compared with other histology types, highlighting variability in surgical outcomes across ovarian cancer subtypes.
"Prognosis" written on blackboard | Image Credit: Yury Zap - stock.adobe.com
June 20th 2024

Surgery Plus Chemotherapy Shows Promise for Stage IV Epithelial Ovarian Cancer

Brooke McCormick
Patients with stage IV epithelial ovarian cancer (OC) treated with surgery and chemotherapy exhibit the best prognosis.
Female patient checking thyroid gland | Image Credit: Jo Panuwat D - stock.adobe.com
June 10th 2024

Hyperthyroidism Potentially Linked to Increased Ovarian Cancer Risk

Brooke McCormick
There may be a causal relaPatients with hyperthyroidism are at increased risk of ovarian cancer (OC), although the link between the conditions is not yet fully understood.
Salad, weights, and measuring tape | Image Credit: freebird7977 - stock.adobe.com
May 28th 2024

Exercise, Diet Interventions Boost Fat-Free Mass, Reduce Fatigue in Patients With OC

Brooke McCormick
Exercise and dietary interventions reduced fatigue and improved both fat-free mass and physical functioning in patients with ovarian cancer (OC), but no significant differences in improvement were found between the intervention and control groups.
Animation of a liver with cancer cell growth | Image Credit: Rasi - stock.adobe.com
May 21st 2024

Surgery, Chemotherapy Considered Protective Survival Factors in Patients With OC, Liver Metastases

Brooke McCormick
Surgery and chemotherapy significantly improved both overall survival (OS) and cancer-specific survival (CSS) in patients with liver metastases originating from ovarian cancer (OC), who generally face a poor prognosis with a 5-year survival rate of less than 30%.
What We’re Reading: Genetic Markers Predict Weight Loss Response; Talc Baby Powder Linked to Ovarian Cancer; Safeguard for IVF Access Nationwide
May 20th 2024

What We’re Reading: Predicting Weight Loss Response; Talc Baby Powder and Ovarian Cancer; Safeguarding IVF Access

AJMC Staff
Certain genes have been linked to significant weight reduction in obesity treatment; research boosts plaintiffs’ cases against Johnson & Johnson for their talc-based baby powder; proposed legislation aims to address concerns following Alabama Supreme Court ruling on embryos.
12345>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo